PARP1 and tuberculosis: We further show that adjunctive use of the FDA-approved PARP1 inhibitor talazoparib (Tp) potently reduces TB lesion size and lung inflammation in mice, potentially by dampening type 1 IFN signaling and neutrophilic inflammation.